Immunome Inc Cash Flow Conversion Efficiency
Immunome Inc cash flow conversion efficiency. Based on the latest financial reports, Immunome Inc (IMNM) has a cash flow conversion efficiency ratio of -0.117x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-61.69 Million) by net assets ($525.08 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Immunome Inc (2018–2025)
Cash flow conversion efficiency of Immunome Inc from 2018 to 2025. This chart illustrates how Immunome Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Immunome Inc share price for real-time trading data and today's change.
Immunome Inc Cash Flow Conversion Ratio Explained
Immunome Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Immunome Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Immunome Inc ranked by their cash flow conversion efficiency. Also see Immunome Inc stock valuation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
National Energy Services Reunited Corp Ordinary Shares
NASDAQ:NESR
|
0.167x |
|
Electric Connector Technology Co Ltd
SHE:300679
|
0.050x |
|
Foran Energy Group Co Ltd
SHE:002911
|
-0.014x |
|
BioCryst Pharmaceuticals Inc
NASDAQ:BCRX
|
0.112x |
|
LTC Properties Inc
NYSE:LTC
|
0.049x |
|
Enterprise Financial Services
NASDAQ:EFSC
|
0.034x |
|
Tiger Brands Ltd
JSE:TBS
|
0.166x |
|
CENTRAL PUERTO ADR/1 AP1
F:C3TA
|
0.074x |
Annual Cash Flow Conversion Efficiency for Immunome Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Immunome Inc from 2018 to 2025. Review Immunome Inc (IMNM) free cash flow to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $634.34 Million | $-190.92 Million | -0.301x | +50.79% |
| 2024-12-31 | $181.16 Million | $-110.79 Million | -0.612x | -868.76% |
| 2023-12-31 | $119.88 Million | $-7.57 Million | -0.063x | +96.34% |
| 2022-12-31 | $16.65 Million | $-28.69 Million | -1.723x | -355.47% |
| 2021-12-31 | $48.19 Million | $-18.23 Million | -0.378x | -28.88% |
| 2020-12-31 | $41.34 Million | $-12.13 Million | -0.293x | -208.92% |
| 2019-12-31 | $-35.63 Million | $-9.60 Million | 0.269x | -8.30% |
| 2018-12-31 | $-25.20 Million | $-7.41 Million | 0.294x | -- |
About Immunome Inc
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine… Read more